For immediate release

PRESS RELEASE

BOOST Pharma Appoints Louise Himmelstrup as Chief Regulatory Officer

Stockholm, Sweden – December 5, 2025 – BOOST Pharma announces the appointment of Louise Himmelstrup as Chief Regulatory Officer. Louise brings a distinguished track record in global regulatory strategy, previously advancing regulatory pathways for leading therapies in the biotech sector. Her decision to join BOOST Pharma underscores both the strength of the company's technology and the anticipated trajectory for clinical and commercial milestones.

Louise Himmelstrup stated, "BOOST Pharma's pioneering approach to cell therapy for Osteogenesis Imperfecta is exactly the kind of innovation I want to champion. I am excited to help guide our therapies through regulatory pathways and ultimately to patients who need them most." Louise's expertise will support upcoming regulatory milestones, including scientific advice meetings with EMA and FDA, planned IND/CTA submissions in the coming year, and the initiation of a pivotal trial for our lead asset.

Hans Schambye, board member of BOOST Pharma, said, "Louise gives us exactly the experience we need as we move toward key milestones and interactions with the FDA and EMA, and she will help us execute our program efficiently."

BOOST Pharma's cell therapy platform builds on years of collaborative research from the Karolinska Institute, targeting next-generation treatments for brittle bone disease. For more information, visit BOOST Pharma's website.

About BOOST Pharma

BOOST Pharma is a clinical-stage biopharmaceutical company focused on the development of novel cell therapy treatments. The company is currently developing a first-in-class therapy to treat Osteogenesis Imperfecta, a severe, inherited rare genetic disease leading to significant physical disability. BOOST Pharma is backed by Sound Bioventures, Industrifonden, BII and Karolinska Development.

About Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI), also know as Brittle Bone Disease, is a rare and devastating genetic disease, with currently no approved therapies. OI is characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints, and weakened teeth. In severe cases, those with OI may experience hundreds of fractures in a lifetime. In addition, people with OI often suffer muscle weakness, early hearing loss, fatigue, curved bones, scoliosis, respiratory problems, and short stature, leading to significant effects on overall health and quality of life. Current treatment of OI is only supportive, focusing on minimizing fractures and maximizing mobility, but to date,

there are no FDA or EU approved treatments. OI is estimated to affect at least 1 in 15,000 people globally.

For further information, please contact:

Hans Schambye, Board member
Email: Hans.Schambye@boostpharma.com